8 Forhøjede levertransaminaser Der blev set forbigående stigninger af ALAT/ ASAT til > 3 gange øvre referencegrænse hos 2, 1% af de patienter, der fik tocilizumab 8 mg/ kg, sammenlignet med 4, 9% af de patienter, der fik MTX og hos 6, 5% af de patienter, der fik 8 mg/ kg tocilizumab plus DMARDs, sammenlignet med 1, 5% af de patienter, der fik placebo plus DMARDs.
8 Hepatic transaminase elevations Transient elevations in ALT/ AST > 3 x ULN were observed in 2.1% of patients on tocilizumab 8 mg/ kg compared to 4.9% of patients on MTX and in 6.5% of patients who received 8 mg/ kg tocilizumab plus DMARDs compared to 1.5% of patients on placebo plus DMARDs.